ARTICLE | Company News
CeNeS in Cangene reformulation deal
February 7, 2001 8:00 AM UTC
CeNeS (LSE:CEN) will develop for Cangene (TSE:CNJ) a sustained release formulation of an undisclosed biopharmaceutical using its Depocore technology. CEN will receive an initial fee to develop and tes...